GNC Holdings, Inc.
| Company Name | GNC Holdings, Inc. |
| Stock Symbol | GNC |
| Status | 1 |
The Firm is investigating potential claims on behalf of investors of GNC Holdings, Inc. ("GNC" or the "Company") (Nasdaq: GNC). The investigation concerns the Company’s and its officers’ possible violations of federal securities laws by issuing materially misleading information to the investing public. Investors who have lost on their investment are encouraged to contact GPM at 310-201-9150.
On October 22, 2015, news reports announced that Oregon's attorney general charged GNC with knowingly selling products spiked with two synthetic drugs. According to news reports, the suit accuses GNC of selling thousands of units of 22 workout and fat-burner supplement products that contained picamilon, a drug used to treat neurological conditions. The suit also alleges that GNC sold other workout and weight-loss supplements that contained a synthetic amphetamine-like chemical known as Beta-methylphenethylamine.
On this news, shares of GNC fell $5.73, or more than 14%, to close at $34.50 on October 22, 2015, thereby damaging investors.
If you purchased GNC securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224 or by email to shareholders@glancylaw.com.
Submit Your Information
If you suffered a loss on your GNC Holdings, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.